Company Filing History:
1 out of 832,891 Years Active: 2012
Title: Konstanze Döhner: Innovator in Acute Myeloid Leukemia Treatment
Introduction
Konstanze Döhner is a prominent inventor based in Neu-Ulm, Germany. She has made significant contributions to the field of medicine, particularly in the treatment of acute myeloid leukemia (AML). Her innovative approach focuses on utilizing all-trans retinoic acid for the development of targeted pharmaceutical compositions.
Latest Patents
Döhner holds a patent for a diagnostic assay aimed at the specific treatment of acute myeloid leukemia. The patent outlines the use of all-trans retinoic acid, emphasizing the selection of patients based on their MN1 levels in total blood cells or bone marrow cells. This method allows for a more personalized treatment approach, enhancing the efficacy of the therapy for non-M3 acute myeloid leukemia patients. The critical level of MN1 can be determined using established methods, such as specific anti-MN1 antibodies in immunoassays.
Career Highlights
Throughout her career, Konstanze Döhner has been recognized for her groundbreaking work in hematology. Her research has paved the way for advancements in the understanding and treatment of acute myeloid leukemia. Döhner's dedication to improving patient outcomes through innovative therapies has established her as a leading figure in her field.
Collaborations
Döhner has collaborated with notable colleagues, including Michael Heuser and Arnold Ganser. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of her work.
Conclusion
Konstanze Döhner's contributions to the treatment of acute myeloid leukemia exemplify the importance of innovation in medicine. Her patent for a diagnostic assay represents a significant step forward in personalized cancer treatment. Through her research and collaborations, Döhner continues to influence the field and improve the lives of patients facing this challenging disease.